AbbVie Becomes Latest To License PD-1xVEGF Bispecific In Growing Field

 
• By Alaric DeArment
  
AbbVie announced a deal with RemeGen for its anti-PD-1/VEGF bispecific antibody, RC148. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business